tiprankstipranks
Trending News
More News >
Vigil Neuroscience Inc (VIGL)
NASDAQ:VIGL
US Market

Vigil Neuroscience, Inc. (VIGL) AI Stock Analysis

Compare
406 Followers

Top Page

VI

Vigil Neuroscience, Inc.

(NASDAQ:VIGL)

Rating:35Underperform
Price Target:
Vigil Neuroscience Inc's stock score is primarily affected by its weak financial performance, characterized by no revenue generation and negative cash flows. The technical analysis shows some short-term positive momentum, but valuation concerns and the overbought condition suggest caution. The lack of earnings call and corporate events data means these factors did not influence the score.
Positive Factors
Acquisition
Sanofi has agreed to acquire Vigil Neuroscience for $470 million upfront, with an additional $2 per share contingent on the commercial success of Vigil’s Alzheimer’s drug, VG-3927.
Drug Development
VG-3927 could have superior attributes to the TREM2/abeta/tau antibodies.
Negative Factors
Asset Exclusion
VGL101 (iluzanebart) will not be acquired by Sanofi in the transaction and will return to Amgen, the original licensor.
Stock Rating
Vigil shares are downgraded from Outperform to Market Perform, although shares are expected to trade near the $8/share cash payout.

Vigil Neuroscience, Inc. (VIGL) vs. SPDR S&P 500 ETF (SPY)

Vigil Neuroscience, Inc. Business Overview & Revenue Model

Company DescriptionVigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
How the Company Makes MoneyVigil Neuroscience Inc generates revenue primarily through strategic partnerships, collaborations, and potential licensing agreements with other pharmaceutical and biotechnology companies. These partnerships often involve milestone payments, research and development funding, and royalties on future product sales. The company may also secure grants and funding from governmental or non-governmental organizations to support its research initiatives. Additionally, as its products progress through clinical trials and reach commercialization, Vigil Neuroscience may generate revenue from the direct sales of its therapeutic products. However, as of the latest available data, the company is likely still in the pre-revenue stage, focusing heavily on research and development activities.

Vigil Neuroscience, Inc. Financial Statement Overview

Summary
Vigil Neuroscience Inc is facing significant financial challenges, with zero revenue and persistent losses. The balance sheet shows some improvement in equity, but overall financial health remains weak due to negative cash flows and high accumulated losses.
Income Statement
10
Very Negative
Vigil Neuroscience Inc has consistently reported zero revenue over the past years, resulting in negative EBIT and net income. The lack of revenue and high losses indicate a challenging financial position. The company's gross and net profit margins are non-existent, highlighting the absence of income generation.
Balance Sheet
30
Negative
The company's balance sheet shows a moderate debt-to-equity ratio, but this is complicated by the negative stockholders' equity in earlier years, which reflects financial instability. The equity ratio is improving, with positive equity in recent years, but overall financial health remains weak. The availability of cash and short-term investments provides some liquidity, but the high accumulated losses are concerning.
Cash Flow
15
Very Negative
Vigil Neuroscience Inc exhibits negative free cash flow, indicating that the company is not generating enough cash to cover its operations and capital expenditures. The operating cash flow to net income ratio is consistently negative, reflecting inadequate cash generation relative to net losses. Free cash flow has not shown significant improvement, suggesting ongoing cash flow challenges.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
1.93M0.000.000.000.000.00
Gross Profit
1.59M0.00-399.00K-1.01M-345.00K0.00
EBIT
-88.43M-89.68M-88.87M-68.88M-42.41M-6.29M
EBITDA
-87.97M-89.68M-88.47M-67.30M-42.94M-28.55M
Net Income Common Stockholders
-82.60M-84.26M-82.64M-67.73M-43.25M-28.55M
Balance SheetCash, Cash Equivalents and Short-Term Investments
24.15M97.80M117.94M186.60M91.42M24.15M
Total Assets
25.30M117.69M140.86M200.39M102.44M25.30M
Total Debt
303.00K12.95M13.85M176.00K937.00K303.00
Net Debt
-23.85M-26.07M-38.14M-186.43M-90.48M-24.15M
Total Liabilities
6.54M46.06M24.61M11.31M171.88M53.58M
Stockholders Equity
18.75M71.64M116.25M189.08M-69.44M-28.28M
Cash FlowFree Cash Flow
-48.61M-51.23M-71.04M-66.07M-39.55M-5.68M
Operating Cash Flow
-48.59M-51.22M-70.36M-65.15M-39.35M-5.18M
Investing Cash Flow
11.59M8.76M-65.14M-921.00K-204.00K-500.00K
Financing Cash Flow
25.11M29.49M888.00K161.25M107.75M29.83M

Vigil Neuroscience, Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price7.89
Price Trends
50DMA
2.34
Positive
100DMA
2.33
Positive
200DMA
2.73
Positive
Market Momentum
MACD
1.14
Negative
RSI
90.55
Negative
STOCH
98.83
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VIGL, the sentiment is Positive. The current price of 7.89 is above the 20-day moving average (MA) of 3.25, above the 50-day MA of 2.34, and above the 200-day MA of 2.73, indicating a bullish trend. The MACD of 1.14 indicates Negative momentum. The RSI at 90.55 is Negative, neither overbought nor oversold. The STOCH value of 98.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VIGL.

Vigil Neuroscience, Inc. Risk Analysis

Vigil Neuroscience, Inc. disclosed 72 risk factors in its most recent earnings report. Vigil Neuroscience, Inc. reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Our board of directors has the authority, without stockholder approval, to issue preferred stock which may include rights superior to the rights of the holders of common stock. The conversion of such preferred stock to common stock and any potential resales could adversely affect the market price of our common stock and result in dilution to existing shareholders. Q4, 2024

Vigil Neuroscience, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
53
Neutral
$5.14B3.23-45.01%2.85%17.55%-0.69%
48
Neutral
$63.43M-197.92%76.04%
45
Neutral
$80.69M-22.38%
44
Neutral
$94.86M-52.76%-70.31%-11.68%
37
Underperform
$105.44M-154.55%19.70%
35
Underperform
$368.24M-102.70%3.01%
28
Underperform
$66.73M-2355.27%-100.00%52.65%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VIGL
Vigil Neuroscience, Inc.
7.88
4.57
138.07%
ACHV
Achieve Life Sciences
3.04
-2.32
-43.28%
XCUR
Exicure
10.04
8.24
457.78%
IMAB
I-MAB
0.99
-0.75
-43.10%
UNCY
Unicycive Therapeutics
0.59
-0.25
-29.76%
CRBU
Caribou Biosciences
1.02
-1.97
-65.89%

Vigil Neuroscience, Inc. Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Vigil Neuroscience Announces Positive Phase 1 Trial Results
Positive
Jan 23, 2025

On January 23, 2025, Vigil Neuroscience announced positive results from its completed Phase 1 clinical trial of VG-3927, a small molecule TREM2 agonist, aimed at treating Alzheimer’s disease. The trial demonstrated a favorable safety and tolerability profile, along with significant pharmacokinetic and pharmacodynamic markers, supporting the drug’s advancement to a Phase 2 trial scheduled for the third quarter of 2025. This development positions VG-3927 as a promising once-daily oral therapy that could offer a more convenient treatment option for Alzheimer’s patients, potentially addressing disease progression beyond targeting amyloid plaques.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.